iFSP1

立即咨询

iFSP1

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

150651-39-1

包装与价格：

包装	价格(元)
10 mM * 1 mL in DMSO	电议
10mg	电议
50mg	电议
100mg	电议
200mg	电议
500mg	电议

产品介绍

iFSP1 是FSP1(AIFM2) 的选择性有效抑制剂，EC₅₀值为 103 nM。iFSP1 可选择性地诱导过表达 FSP1 的 GPX4 敲除细胞发生铁死亡 (ferroptosis)。iFSP1 可增强多种人癌细胞系对铁死亡诱导剂的敏感度，如: (1S,3R)-RSL3 (HY-100218A)。

生物活性

iFSP1 is a potent, selective and glutathione-independent inhibitor offerroptosissuppressor protein 1 (FSP1)(AIFM2) with anEC₅₀of 103 nM. iFSP1 selectively inducesferroptosisin GPX4-knockout cells which overexpressed FSP1. iFSP1 is able to sensitize a variety of humancancercell lines to theferroptosisinducer, such as (1S,3R)-RSL3 (HY-100218A)^[1].

IC₅₀& Target

EC50: 103 nM (FSP1)^[1]

体外研究
(In Vitro)

iFSP1 (0.001-1 μM; 24 hours) inhibits the Gpx4-knockout cell growth as a dose-dependent manner, but does not inhibit the wild type cell growth. Treatment with the ferroptosis inhibitor Lip-1 protects GPX4- knockout cells from iFSP1-induced ferroptosis^[1].
iFSP1 (0.001-1 μM; 24 hours) is less efficient than genetic deletion of FSP1, whereas iFSP1 treatment in the FSP1-knockout background had no additive effect to RSL3-induced ferroptosis^[1].
iFSP1 (3 μM; 24 hours) treatment results in an obvious toxicity of RSL3 in a panel of genetically engineered (FSP1-knockout) human cancer cell lines^[1].
AIFM2: the flavoprotein apoptosis-inducing factor mitochondria-associated 2 is a previously unrecognized anti-ferroptotic gene. AIFM2, which is renamed ferroptosis suppressor protein 1 (FSP1)^[1]

Cell Proliferation Assay^[1]

Cell Line:	Wild-type and Gpx4-knockout Pfa1 or HT 1080 cells overexpressing FSP1–HA
Concentration:	0.001-1 μM
Incubation Time:	24 hours
Result:	Was toxic to cells that depend solely (no GPX4 expression detectable) on FSP1 function.

Cell Viability Assay^[1]

Cell Line:	NCl-H1437, NCl-H1437 FSP1 KO, U-373, U-373 FSP1 KO, MDA-MB-436, MDA-MB-436 FSP1 KO, SW620, SW620 FSP1 KO, MDA-MB-435S, MDA-MB-435S FSP1 KO, A549 and A549 FSP1 KO
Concentration:	3 μM
Incubation Time:	24 hours
Result:	Sensitized a variety of human cancer cell lines to the ferroptosis inducer (1S,3R)-RSL3.

分子量

323.35

性状

Solid

Formula

C₂₀H₁₃N₅

CAS 号

150651-39-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 20 mg/mL(61.85 mM;Need ultrasonic)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM	3.0926 mL	15.4631 mL	30.9262 mL
5 mM	0.6185 mL	3.0926 mL	6.1852 mL
10 mM	0.3093 mL	1.5463 mL	3.0926 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.
请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline
Solubility: 2 mg/mL (6.19 mM); Suspended solution; Need ultrasonic
此方案可获得 2 mg/mL (6.19 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液

*以上所有助溶剂都可在本网站选购。